Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
Hyun Jeong Jeon (Jeon HJ), Tae Keun Oh (Oh TK)
Diabetes Metab J. 2011;35(5):529-535.   Published online 2011 Oct 31     DOI: https://doi.org/10.4093/dmj.2011.35.5.529
Citations to this article as recorded by Crossref logo
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease
Rehab Werida, Mahmoud Kabel, Gamal Omran, Ahmed Shokry, Tarek Mostafa
Diabetes Research and Clinical Practice.2020; 170: 108473.     CrossRef
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta‐analysis involving eight eligible randomized‐controlled trials
Yan Peng, Shu‐Hong Chen, Xiao‐Nan Liu, Qing‐Yun Sun
Journal of Cellular Physiology.2019; 234(3): 2795.     CrossRef
A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis
Daniela Farah, Graziella Malzoni Leme, Freddy Goldberg Eliaschewitz, Marcelo Cunio Machado Fonseca
Diabetes Research and Clinical Practice.2019; 149: 47.     CrossRef
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial
Yu Hong Chen, Chien-Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang, Wei Qing Wang
Diabetes, Obesity and Metabolism.2018; 20(9): 2121.     CrossRef
Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou, John Yfantopoulos
Cost Effectiveness and Resource Allocation.2017;[Epub]     CrossRef
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee
Expert Opinion on Pharmacotherapy.2017; 18(12): 1179.     CrossRef
Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
Helene Bihan, Winda L. Ng, Dianna J. Magliano, Jonathan E. Shaw
Diabetes Research and Clinical Practice.2016; 121: 27.     CrossRef
New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?
Udaya M Kabadi
Journal of Diabetes, Metabolic Disorders & Control.2016;[Epub]     CrossRef
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
Eleni Bekiari, Chrysoula Rizava, Eleni Athanasiadou, Konstantinos Papatheodorou, Aris Liakos, Thomas Karagiannis, Maria Mainou, Maria Rika, Panagiota Boura, Apostolos Tsapas
Endocrine.2016; 52(3): 458.     CrossRef
Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes
Udaya M. Kabadi
Journal of Diabetes Mellitus.2015; 05(04): 211.     CrossRef
Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study (印度2型糖尿病患者使用维格列汀与二甲双胍联合治疗对血糖的影响:一项观察性研究)
Sanjay Chatterjee, Sudip Chatterjee
Journal of Diabetes.2014; 6(3): 237.     CrossRef
Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
Yifei Zhang, Jie Hong, Jie Chi, Weiqiong Gu, Guang Ning, Weiqing Wang
Diabetes/Metabolism Research and Reviews.2014; 30(3): 241.     CrossRef
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Gillian M. Keating
Drugs.2014; 74(5): 587.     CrossRef
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients
Giuseppe Derosa, Aldo Bonaventura, Lucio Bianchi, Davide Romano, Elena Fogari, Angela D’Angelo, Pamela Maffioli
Metabolism.2014; 63(7): 957.     CrossRef
The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes
Jaime A. Davidson
Endocrine Practice.2013; 19(6): 1050.     CrossRef
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
Jin-Sun Chang, Juyoung Shin, Hun-Sung Kim, Kyung-Hee Kim, Jeong-Ah Shin, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Jae-Hyoung Cho
Diabetes & Metabolism Journal.2013; 37(1): 72.     CrossRef
The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
Jun Sung Moon, Kyu Chang Won
Diabetes & Metabolism Journal.2013; 37(1): 36.     CrossRef
Effect of Vildagliptin on Glucose and Insulin Concentrations During a 24-Hour Period in Type 2 Diabetes Patients with Different Ranges of Baseline Hemoglobin A1c Levels
Manuel González-Ortiz, María J. Sánchez-Peña, Luis J. González-Ortiz, José A. Robles-Cervantes, Yessica E. García-Ortega, Esteban A. Gómez-Gaitán, Karina G. Pérez-Rubio, Esperanza Martínez-Abundis
Diabetes Technology & Therapeutics.2013; 15(7): 564.     CrossRef
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
Y. L. He, G. Foteinos, S. Neelakantham, D. Mattapalli, K. Kulmatycki, T. Forst, A. Taylor
Diabetes, Obesity and Metabolism.2013; 15(12): 1111.     CrossRef
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus
Elisa Guarino, Laura Nigi, Aurora Patti, Cecilia Fondelli, Francesco Dotta
Expert Opinion on Pharmacotherapy.2012; 13(9): 1377.     CrossRef